多巴胺受体激动剂对雌激素诱导F344大鼠垂体泌乳素腺瘤的治疗作用

Therapeutic effect of dopamine receptor agonist on estrogen-induced pituitary prolactinomas in Fisher 344 rats

目的观察溴隐亭对雌激素诱导Fisher344（F344）大鼠垂体泌乳素腺瘤的治疗作用及雌激素受体（ER）ERα、ERp、多巴胺2型受体（D：R）的表达。方法采用免疫组织化学sP法检测泌乳素（PRL）、ERa、ERp及D：R在垂体组织中的表达，放射免疫法检测血清PRL水平。结果模型组血清PRL水平（3579．8±412．5）μg/L与对照组（19．6±5．2）μg／L比较显著增高，治疗组（110．8±21．3）μg/L明显降低（P〈0．01）。模型组与治疗组ERa的表达水平高于对照组；治疗组ERD的表达水平高于另两组；D：R在3组中的表达差异无统计学意义（P〉0．05）。结论溴隐亭可抑制雌激素诱导的F344大鼠泌乳素腺瘤生长及PRL分泌，具有治疗作用。ER可能在泌乳素腺瘤的发生发展中具有重要作用。

Objective To investigate the therapeutic effect of bromocryptine on estrogen-induced pituitary prolactinomas in F344 rats and observe the expression levels of estrogen receptor （ER） ERα, ERβ and dopamine D2 receptor （DE R）. Methods Prolactin （PRL）, ERα, ERβ and D2R expressions were detected by immunohistochemistry in pituitary gland. Radioimmunoassay was employed to detect serum PRL level. Results The Serum PRL level of the model group increased significantly compared with the control group, which were （3579. 8±412. 5） μg/L and （ 19. 6 ±5.2） μg/L, separately. The serum PRL level （110. 8±21.3） μg/L of the therapeutic group was decreased （P 〈0.01 ）. The expression levels of ERα in prolactinomas of the model group and the therapeutic group were higher than the control group; ERβ expression level in the therapeutic group was higher than the other two groups. There were no differences in D2R expressions among the three groups （ P 〉 0. 05 ）. Conclusion Bromocryptine might have therapeutic effects on estrogen-induced pituitary prolactinoma through inhibiting PRL secretion and tumor growth. ER might play an important role in prolactinomas tumorigenesis and development.